

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2013

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No. 1-2189

**ABBOTT LABORATORIES**

An Illinois Corporation

I.R.S. Employer Identification No.  
36-0698440

100 Abbott Park Road  
Abbott Park, Illinois 60064-6400

Telephone: (847) 937-6100

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer   
(Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of June 30, 2013, Abbott Laboratories had 1,554,125,355 common shares without par value outstanding.

PART I. FINANCIAL INFORMATION

Abbott Laboratories and Subsidiaries

Condensed Consolidated Financial Statements

(Unaudited)

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars and shares in thousands except per share data)

|  | Three Months Ended<br>June 30 |              | Six Months Ended<br>June 30 |               |
|--|-------------------------------|--------------|-----------------------------|---------------|
|  | 2013                          | 2012         | 2013                        | 2012          |
| Net Sales  | \$ 5,446,025                  | \$ 5,313,297 | \$ 10,823,920               | \$ 10,596,982 |
| Cost of products sold  | 2,544,825                     | 2,370,056    | 4,976,628                   | 4,729,220     |
| Amortization of intangible assets  | 196,892                       | 194,823      | 396,314                     | 404,413       |
| Research and development   | 362,557                       | 370,605      | 708,880                     | 734,319       |
| Selling, general and administrative  | 1,714,275                     | 1,813,623    | 3,499,834                   | 3,655,655     |
| Total Operating Cost and Expenses  | 4,818,549                     | 4,749,107    | 9,581,656                   | 9,523,607     |
| Operating Earnings   | 627,476                       | 564,190      | 1,242,264                   | 1,073,375     |
| Interest expense   | 40,526                        | 83,288       | 81,283                      | 165,368       |
| Interest (income)  | (16,901)                      | (18,889)     | (31,951)                    | (35,155)      |
| Net foreign exchange loss (gain)   | 10,748                        | (24,536)     | 39,613                      | (9,630)       |
| Other (income) expense, net  | (7,646)                       | (5,177)      | (1,981)                     | (40,088)      |
| Earnings from Continuing Operations Before Taxes   | 600,749                       | 529,504      | 1,155,300                   | 992,880       |
| Taxes on Earnings from Continuing Operations   | 124,694                       | 118,663      | 134,584                     | 230,824       |
| Earnings from Continuing Operations  | 476,055                       | 410,841      | 1,020,716                   | 762,056       |
| Earnings from Discontinued Operations, net of taxes  | —                             | 1,313,771    | —                           | 2,204,680     |
| Net Earnings   | \$ 476,055                    | \$ 1,724,612 | \$ 1,020,716                | \$ 2,966,736  |
| Basic Earnings Per Common Share —  |                               |              |                             |               |
| Continuing Operations  | \$ 0.30                       | \$ 0.26      | \$ 0.65                     | \$ 0.48       |
| Discontinued Operations  | —                             | 0.83         | —                           | 1.39          |
| Net Earnings   | \$ 0.30                       | \$ 1.09      | \$ 0.65                     | \$ 1.87       |
| Diluted Earnings Per Common Share —  |                               |              |                             |               |
| Continuing Operations  | \$ 0.30                       | \$ 0.26      | \$ 0.64                     | \$ 0.47       |
| Discontinued Operations  | —                             | 0.82         | —                           | 1.38          |
| Net Earnings   | \$ 0.30                       | \$ 1.08      | \$ 0.64                     | \$ 1.85       |
| Cash Dividends Declared Per Common Share   | \$ 0.14                       | \$ 0.51      | \$ 0.28                     | \$ 1.02       |
| Average Number of Common Shares Outstanding Used for   |                               |              |                             |               |
| Basic Earnings Per Common Share  | 1,560,519                     | 1,572,099    | 1,564,894                   | 1,572,681     |
| Dilutive Common Stock Options and Awards   | 16,165                        | 16,403       | 16,726                      | 15,996        |
| Average Number of Common Shares Outstanding Plus Dilutive<br>Common Stock Options and Awards | 1,576,684                     | 1,588,502    | 1,581,620                   | 1,588,677     |
| Outstanding Common Stock Options Having No Dilutive Effect                                   | 1,015                         | 1,166        | 1,015                       | 1,166         |

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

2

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars thousands)

|   | Three Months Ended<br>June 30 |              | Six Months Ended<br>June 30 |              |
|---|-------------------------------|--------------|-----------------------------|--------------|
|   | 2013                          | 2012         | 2013                        | 2012         |
| Net Income  | \$ 476,055                    | \$ 1,724,612 | \$ 1,020,716                | \$ 2,966,736 |
| Less: Income from Discontinued Operations   | —                             | 1,313,771    | —                           | 2,204,680    |
| Earnings from Continuing Operations   | 476,055                       | 410,841      | 1,020,716                   | 762,056      |
| Foreign currency translation (loss) adjustments   | (359,578)                     | (1,126,230)  | (600,469)                   | (687,427)    |
| Net actuarial (losses) and amortization of net actuarial losses and<br>prior service cost and credits, net of taxes of \$15,617 and<br>\$(41,149) in 2013 and \$22,794 and \$45,615 in 2012 | 27,958                        | 39,588       | (163,307)                   | 79,212       |
| Unrealized gains on marketable equity securities, net of taxes of<br>\$1,408 and \$1,866 in 2013 and \$433 and \$2,441 in 2012  | 2,439                         | 741          | 3,233                       | 4,219        |
| Net adjustments for derivative instruments designated as cash   | (2,571)                       | 3,163        | (23,493)                    | (42,023)     |

|   |                   |                   |                   |                     |
|---|-------------------|-------------------|-------------------|---------------------|
| flow hedges and other, net of taxes of \$(643) and \$(5,873) in 2013 and \$1,112 and \$(11,127) in 2012 |                   |                   |                   |                     |
| Other Comprehensive (Loss) from Continuing Operations   | (331,752)         | (1,082,738)       | (784,036)         | (646,019)           |
| Comprehensive Income (Loss) from Continuing Operations  | 144,303           | (671,897)         | 236,680           | 116,037             |
| Comprehensive Income from Discontinued Operations   | —                 | 794,098           | —                 | 1,904,353           |
| Comprehensive Income  | <u>\$ 144,303</u> | <u>\$ 122,201</u> | <u>\$ 236,680</u> | <u>\$ 2,020,390</u> |

|  | <u>June 30</u><br><u>2013</u> | <u>December 31</u><br><u>2012</u> |
|--|-------------------------------|-----------------------------------|
| Supplemental Accumulated Other Comprehensive Income Information, net of tax: |                               |                                   |
| Cumulative foreign currency translation loss adjustments                     | \$ (887,058)                  | \$ (79,353)                       |
| Net actuarial losses and prior service cost and credits                      | (2,408,363)                   | (3,595,554)                       |
| Cumulative unrealized gains on marketable equity securities                  | 33,973                        | 31,363                            |
| Cumulative gains on derivative instruments designated as cash flow hedges    | 35,023                        | 49,866                            |

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

3

Abbott Laboratories and Subsidiaries  
Condensed Consolidated Statement of Cash Flows  
(Unaudited)  
(dollars in thousands)

|   | <u>Six Months Ended June 30</u> |                     |
|---|---------------------------------|---------------------|
|   | <u>2013</u>                     | <u>2012</u>         |
| Cash Flow From (Used in) Operating Activities:                            |                                 |                     |
| Net earnings  | \$ 1,020,716                    | \$ 2,966,736        |
| Adjustments to reconcile earnings to net cash from operating activities - |                                 |                     |
| Depreciation  | 460,369                         | 675,097             |
| Amortization of intangibles   | 396,314                         | 759,605             |
| Share-based compensation  | 177,294                         | 283,127             |
| Acquired in-process and collaborations research and development           | —                               | 260,000             |
| Trade receivables   | (90,823)                        | 743,512             |
| Inventories   | (232,247)                       | (379,478)           |
| Other, net  | (554,809)                       | (1,016,840)         |
| Net Cash From Operating Activities  | <u>1,176,814</u>                | <u>4,291,759</u>    |
| Cash Flow From (Used in) Investing Activities:                            |                                 |                     |
| Acquisitions of property and equipment                                    | (564,884)                       | (878,446)           |
| Acquisitions of businesses and technology                                 | —                               | (660,000)           |
| Purchases of investment securities, net                                   | (1,507,053)                     | (2,677,257)         |
| Other   | —                               | 12,308              |
| Net Cash (Used in) Investing Activities                                   | <u>(2,071,937)</u>              | <u>(4,203,395)</u>  |
| Cash Flow From (Used in) Financing Activities:                            |                                 |                     |
| Proceeds from issuance of short-term debt and other                       | 3,149,857                       | 2,696,769           |
| Payment of long-term debt   | —                               | (54,000)            |
| Contingent consideration payment related to a business acquisition        | —                               | (120,849)           |
| Transfer of cash and cash equivalents to AbbVie Inc.                      | (5,901,400)                     | —                   |
| Purchases of common shares  | (1,215,151)                     | (1,722,114)         |
| Proceeds from stock options exercised, including income tax benefit       | 142,604                         | 1,046,318           |
| Dividends paid  | (444,097)                       | (1,565,532)         |
| Net Cash (Used in) From Financing Activities                              | <u>(4,268,187)</u>              | <u>280,592</u>      |
| Effect of exchange rate changes on cash and cash equivalents              | (66,599)                        | (129,000)           |
| Net (Decrease) Increase in Cash and Cash Equivalents                      | (5,229,909)                     | 239,956             |
| Cash and Cash Equivalents, Beginning of Year                              | 10,802,163                      | 6,812,820           |
| Cash and Cash Equivalents, End of Period                                  | <u>\$ 5,572,254</u>             | <u>\$ 7,052,776</u> |

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

4

(Unaudited)

(dollars in thousands)

|  | June 30<br>2013      | December 31<br>2012  |
|--|----------------------|----------------------|
| <b>Assets</b>  |                      |                      |
| <b>Current Assets:</b>   |                      |                      |
| Cash and cash equivalents  | \$ 5,572,254         | \$ 10,802,163        |
| Investments, primarily bank time deposits and U.S. treasury bills                  | 3,821,338            | 4,371,821            |
| Trade receivables, less allowances of \$309,950 in 2013 and \$405,921 in 2012      | 3,938,998            | 7,612,860            |
| <b>Inventories:</b>  |                      |                      |
| Finished products  | 1,857,257            | 2,345,455            |
| Work in process  | 353,804              | 628,874              |
| Materials  | 514,118              | 817,984              |
| Total inventories  | 2,725,179            | 3,792,313            |
| Prepaid expenses, deferred income taxes, and other receivables                     | 3,240,172            | 4,743,426            |
| Current assets held for disposition  | 533,183              | —                    |
| <b>Total Current Assets</b>  | <b>19,831,124</b>    | <b>31,322,583</b>    |
| Investments  | 154,268              | 273,595              |
| Property and Equipment, at Cost  | 12,520,032           | 18,928,887           |
| Less: accumulated depreciation and amortization                                    | 6,751,383            | 10,865,840           |
| <b>Net Property and Equipment</b>  | <b>5,768,649</b>     | <b>8,063,047</b>     |
| Intangible Assets, net of amortization   | 5,642,826            | 8,588,285            |
| Goodwill   | 9,357,505            | 15,774,127           |
| Deferred Income Taxes and Other Assets   | 2,077,860            | 3,213,307            |
| Non-current Assets Held for Disposition  | 71,114               | —                    |
|  | <u>\$ 42,903,346</u> | <u>\$ 67,234,944</u> |
| <b>Liabilities and Shareholders' Investment</b>                                    |                      |                      |
| <b>Current Liabilities:</b>  |                      |                      |
| Short-term borrowings  | \$ 4,259,614         | \$ 2,081,839         |
| Trade accounts payable   | 1,042,248            | 1,796,990            |
| Salaries, wages and commissions  | 800,814              | 1,427,765            |
| Other accrued liabilities  | 3,893,569            | 6,787,995            |
| Dividends payable  | 218,048              | 221,340              |
| Income taxes payable   | 138,772              | 655,424              |
| Current portion of long-term debt  | 264,164              | 308,823              |
| Current liabilities held for disposition   | 302,385              | —                    |
| <b>Total Current Liabilities</b>   | <b>10,919,614</b>    | <b>13,280,176</b>    |
| Long-term Debt   | 3,410,759            | 18,085,302           |
| Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities | 6,139,332            | 9,056,234            |
| Non-current Liabilities Held for Disposition                                       | 5,995                | —                    |
| <b>Commitments and Contingencies</b>   |                      |                      |
| <b>Shareholders' Investment:</b>   |                      |                      |
| Preferred shares, one dollar par value Authorized – 1,000,000 shares, none issued  | —                    | —                    |
| Common shares, without par value   |                      |                      |
| Authorized - 2,400,000,000 shares  |                      |                      |
| Issued at stated capital amount -  |                      |                      |
| Shares: 2013: 1,681,959,233; 2012: 1,675,930,484                                   | 11,730,952           | 11,754,552           |
| Common shares held in treasury, at cost -  |                      |                      |
| Shares: 2013: 127,833,878; 2012: 99,262,992  | (6,487,355)          | (5,590,909)          |
| Earnings employed in the business  | 20,318,892           | 24,150,996           |
| Accumulated other comprehensive income (loss)                                      | (3,226,425)          | (3,593,678)          |
| <b>Total Abbott Shareholders' Investment</b>                                       | <b>22,336,064</b>    | <b>26,720,961</b>    |
| Noncontrolling Interests in Subsidiaries   | 91,582               | 92,271               |
| <b>Total Shareholders' Investment</b>  | <b>22,427,646</b>    | <b>26,813,232</b>    |
|  | <u>\$ 42,903,346</u> | <u>\$ 67,234,944</u> |

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

## Abbott Laboratories and Subsidiaries

## Notes to Condensed Consolidated Financial Statements

June 30, 2013  
(Unaudited)

## Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in

the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott's Annual Report on Form 10-K/A for the year ended December 31, 2012. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. The Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2012 has been appropriately revised to reflect a contingent consideration payment related to a business acquisition as cash flow used in financing activities. The amount had been previously reflected as cash flow used in investing activities.

#### Note 2 — Separation of AbbVie Inc.

On November 28, 2012, Abbott's board of directors declared a special dividend distribution of all of the outstanding shares of common stock of AbbVie Inc. (AbbVie), the company formed to hold Abbott's research-based proprietary pharmaceuticals business. For each Abbott common share held at the close of business on December 12, 2012, Abbott shareholders received one share of AbbVie stock on January 1, 2013. Abbott has received a ruling from the Internal Revenue Service that the separation qualifies as a tax-free distribution to Abbott and its U.S. shareholders for U.S. federal income tax purposes.

The historical results of operations of the research-based proprietary pharmaceuticals business have been presented as discontinued operations in the Condensed Consolidated Statement of Earnings. Discontinued operations include the results of AbbVie's business except for certain corporate overhead costs and certain costs associated with transition services that will be provided by Abbott to AbbVie. Discontinued operations also includes other costs incurred by Abbott to separate AbbVie as well as an allocation of interest assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. Prior-year balance sheets and statements of cash flows have not been adjusted to reflect the effect of the separation.

The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013: (*dollars in billions*)

|  |               |
|--|---------------|
| <b>Assets:</b>   |               |
| Cash and cash equivalents  | \$ 5.9        |
| Investments  | 2.2           |
| Trade receivables, less allowances   | 3.2           |
| Inventories  | 0.7           |
| Prepaid expenses, deferred income taxes, and other current receivables             | 2.9           |
| Net property and equipment   | 2.2           |
| Intangible assets, net of amortization   | 2.3           |
| Goodwill   | 6.1           |
| Deferred income taxes and other assets   | 1.6           |
|  | <u>27.1</u>   |
| <b>Liabilities:</b>  |               |
| Short-term borrowings  | 1.0           |
| Trade accounts payable and other current liabilities                               | 5.1           |
| Long-term debt   | 14.6          |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1           |
|  | <u>23.8</u>   |
| Net Assets Transferred to AbbVie Inc.  | <u>\$ 3.3</u> |

In addition, approximately \$1.1 billion of accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation was transferred to AbbVie.

#### Notes to Condensed Consolidated Financial Statements

June 30, 2013

(Unaudited), continued

Summarized financial information for discontinued operations for 2012 is as follows: (*dollars in millions*)

|                       | <b>Three Months Ended<br/>June 30 2012</b> | <b>Six Months Ended<br/>June 30 2012</b> |
|-----------------------|--|--|
| Net sales             | \$ 4,494                                   | \$ 8,667                                 |
| Earnings before taxes | 1,473                                      | 2,523                                    |
| Taxes on earnings     | 159  | 318                                      |
| Net earnings          | 1,314                                      | 2,205                                    |

Abbott and AbbVie entered into transitional services agreements prior to the separation pursuant to which Abbott and AbbVie are providing to each other, on an interim transitional basis, various services. Transition services may be provided for up to 24 months with an option for a one-year extension by the recipient. Services being provided by Abbott include certain information technology and back office support. Billings by Abbott under these transitional services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transitional support will enable AbbVie to establish its stand-alone processes for various activities that were previously provided by Abbott and does not constitute significant continuing support of AbbVie's operations.

For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations are expected to be transferred to AbbVie in 2013 with the remainder transferring in 2014. These assets and liabilities have been presented as held for disposition in the Condensed Consolidated Balance Sheet. At June 30, 2013, the assets and liabilities held for disposition consist of inventories of \$180 million, trade accounts receivable of \$319 million, equipment of \$30 million, other assets of \$75 million, trade accounts payable of \$243 million and other liabilities of \$65 million. Abbott's obligation to transfer the net assets held for disposition to AbbVie of \$296 million is included in Other accrued liabilities.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. In connection with the separation, Abbott has adjusted its employee stock compensation awards and separated its defined benefit programs for pensions and post-employment medical and dental benefit plans. See notes 7 and 9 for additional information.

### Note 3 — Supplemental Financial Information

Unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months and six months ended June 30, 2013 were \$473 million and \$1.013 billion, respectively, and net earnings allocated to common shares for the three months and six months ended June 30, 2012 were \$1.711 billion and \$2.943 billion, respectively.

Other (income) expense, net, for the six months ended June 30, 2012 includes income of approximately \$40 million from the resolution of a contractual agreement. Other, net in Net cash from operating activities for 2012 includes payments of approximately \$800 million to settle certain government investigations related to AbbVie's business operations. Other, net in Net cash from operating activities for 2013 and 2012 includes the effects of contributions to defined benefit plans of approximately \$320 million in each period.

The components of long-term investments as of June 30, 2013 and December 31, 2012 are as follows:

| (dollars in millions) | June 30<br>2013 | December 31<br>2012 |
|-----------------------|-----------------|---------------------|
| Equity securities     | \$ 126          | \$ 213              |
| Other                 | 28              | 61                  |
| <b>Total</b>          | <b>\$ 154</b>   | <b>\$ 274</b>       |

The reduction in long-term investments from December 31, 2012 to June 30, 2013 is due primarily to the separation of AbbVie on January 1, 2013.

### Notes to Condensed Consolidated Financial Statements June 30, 2013 (Unaudited), continued

#### Note 4 — Other Comprehensive Income

The components of the changes in other comprehensive income from continuing operations, net of income taxes, is as follows:

| (dollars in millions)  | Three Months Ended June 30                                |                 |   |                   |  |              |   |               |
|--|---|-----------------|---|-------------------|--|--------------|---|---------------|
|  | Cumulative Foreign<br>Currency Translation<br>Adjustments |                 | Net Actuarial<br>Losses and Prior<br>Service Costs and<br>Credits |                   | Cumulative<br>Unrealized Gains<br>on Marketable<br>Equity Securities |              | Cumulative Gains<br>on Derivative<br>Instruments<br>Designated as Cash<br>Flow Hedges |               |
|  | 2013  | 2012            | 2013  | 2012              | 2013   | 2012         | 2013  | 2012          |
| Balance at March 31  | \$ (527)  | \$ 358          | \$ (2,436)  | \$ (2,626)        | \$ 32  | \$ 15        | \$ 38   | \$ 117        |
| Other comprehensive income before reclassifications                  | (360)   | (1,090)         | —   | —                 | 7  | 5            | 12  | 29            |
| Amounts reclassified from accumulated other comprehensive income (a) | —   | (36)            | 28  | 40                | (5)  | (4)          | (15)  | (26)          |
| Net current period comprehensive income from continuing operations   | (360)   | (1,126)         | 28  | 40                | 2  | 1            | (3)   | 3             |
| <b>Balance at June 30</b>  | <b>\$ (887)</b>   | <b>\$ (768)</b> | <b>\$ (2,408)</b>   | <b>\$ (2,586)</b> | <b>\$ 34</b>   | <b>\$ 16</b> | <b>\$ 35</b>  | <b>\$ 120</b> |

  

| (dollars in millions)  | Six Months Ended June 30                                  |                 |   |                   |  |              |   |               |
|--|---|-----------------|---|-------------------|--|--------------|---|---------------|
|  | Cumulative Foreign<br>Currency Translation<br>Adjustments |                 | Net Actuarial<br>Losses and Prior<br>Service Costs and<br>Credits |                   | Cumulative<br>Unrealized Gains<br>on Marketable<br>Equity Securities |              | Cumulative Gains<br>on Derivative<br>Instruments<br>Designated as Cash<br>Flow Hedges |               |
|  | 2013  | 2012            | 2013  | 2012              | 2013   | 2012         | 2013  | 2012          |
| Balance at December 31, 2012 and 2011                                | \$ (79)   | \$ (73)         | \$ (3,596)  | \$ (2,731)        | \$ 31  | \$ 38        | \$ 50   | \$ 167        |
| Separation of AbbVie   | (208)   | (8)             | 1,351   | 66                | —  | (26)         | 8   | (5)           |
| Other comprehensive income before reclassifications                  | (600)   | (651)           | (219)   | —                 | 14   | 5            | (5)   | (3)           |
| Amounts reclassified from accumulated other comprehensive income (a) | —   | (36)            | 56  | 79                | (11)   | (1)          | (18)  | (39)          |
| Net current period comprehensive income from continuing operations   | (600)   | (687)           | (163)   | 79                | 3  | 4            | (23)  | (42)          |
| <b>Balance at June 30</b>  | <b>\$ (887)</b>   | <b>\$ (768)</b> | <b>\$ (2,408)</b>   | <b>\$ (2,586)</b> | <b>\$ 34</b>   | <b>\$ 16</b> | <b>\$ 35</b>  | <b>\$ 120</b> |

(a) Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange loss (gain); gains on marketable equity securities as Other (income) expense and cash flow hedges as Cost of products sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan costs; see Note 7 for additional details.

#### Note 5 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. The effective tax rates are less than the statutory U.S. federal income tax rate principally due to the benefit of lower statutory tax rates and tax exemptions in several foreign taxing jurisdictions. As a result of the American Taxpayer Relief Act of 2012 signed into law in January 2013, Abbott recorded a tax benefit to taxes on continuing operations of approximately \$103 million in the first quarter of 2013 for the retroactive extension of the research tax credit and the look-through rules of section 954(c)(6) of the Internal Revenue Code to the beginning of 2012. Tax authorities in various jurisdictions regularly review Abbott's income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by \$550 million to \$650 million, including cash adjustments, within the next twelve months as a result of concluding various tax matters.

Notes to Condensed Consolidated Financial Statements  
June 30, 2013  
(Unaudited), continued

Note 6 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed \$4 million, and the aggregate cleanup exposure is not expected to exceed \$15 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately \$65 million to \$90 million. The recorded accrual balance at June 30, 2013 for these proceedings and exposures was approximately \$75 million. This accrual represents management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies." Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

Note 7 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net cost recognized in continuing operations for the three and six months ended June 30 for Abbott's major defined benefit plans and post-employment medical and dental benefit plans is as follows:

| (dollars in millions)                            | Defined Benefit Plans      |       |                          |        | Medical and Dental Plans   |       |                          |       |
|--|----------------------------|-------|--------------------------|--------|----------------------------|-------|--------------------------|-------|
|  | Three Months Ended June 30 |       | Six Months Ended June 30 |        | Three Months Ended June 30 |       | Six Months Ended June 30 |       |
|  | 2013                       | 2012  | 2013                     | 2012   | 2013                       | 2012  | 2013                     | 2012  |
| Service cost — benefits earned during the period | \$ 76                      | \$ 59 | \$ 152                   | \$ 118 | \$ 11                      | \$ 8  | \$ 23                    | \$ 16 |
| Interest cost on projected benefit obligations   | 66                         | 67    | 132                      | 133    | 15                         | 11    | 30                       | 22    |
| Expected return on plans' assets                 | (94)                       | (91)  | (187)                    | (182)  | (9)                        | (4)   | (18)                     | (9)   |
| Net amortization                                 | 41                         | 36    | 82                       | 73     | —                          | (1)   | —                        | (2)   |
| Net Cost   | \$ 89                      | \$ 71 | \$ 179                   | \$ 142 | \$ 17                      | \$ 14 | \$ 35                    | \$ 27 |

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to applicable regulations. In the first six months of 2013 and 2012, approximately \$320 million was contributed to defined benefit plans and \$40 million was contributed to the post-employment medical and dental benefit plans in each period.

The separation agreement with AbbVie obligates Abbott to transfer certain defined benefit and medical and dental plan liabilities and assets to AbbVie. The net obligation is included in the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013. Although the Abbott plans still hold some of the assets included in this net obligation, the AbbVie plans have the right to receive and Abbott has the obligation to complete the transfer of these assets. Any such assets held by an Abbott plan as of June 30, 2013 will be transferred to the applicable AbbVie plan in 2013. The following table summarizes these projected benefit obligations and assets at January 1, 2013:

| (dollars in millions)                | Defined Benefit Plans | Medical and Dental Plans |
|--------------------------------------|-----------------------|--------------------------|
| Projected benefit obligations        | \$ 4,542              | \$ 501                   |
| Plans' assets                        | 3,149                 | —                        |
| Net obligation transferred to AbbVie | \$ 1,393              | \$ 501                   |

In addition, Abbott transferred to AbbVie Accumulated other comprehensive income (loss), net of income taxes, of approximately \$1.2 billion.

Notes to Condensed Consolidated Financial Statements  
June 30, 2013  
(Unaudited), continued

Note 8 — Segment Information

Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott's products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies throughout the world. As a result

of the separation of AbbVie, Abbott no longer has a Proprietary Pharmaceutical Products segment and this business has been removed from the 2012 historical information presented below. Abbott's reportable segments are as follows:

*Established Pharmaceutical Products* — International sales of a broad line of branded generic pharmaceutical products.

*Nutritional Products* — Worldwide sales of a broad line of adult and pediatric nutritional products.

*Diagnostic Products* — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

*Vascular Products* — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, effective January 1, 2013, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment's assets. After removal of intangible assets and goodwill from the measure of segment assets, the assets of the Established Pharmaceutical Products and the Vascular Products segments totaled \$2.5 billion and \$1.7 billion, respectively, as of June 30, 2013. The segment information below for 2012 has been adjusted to exclude intangible asset amortization. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

| (dollars in millions)   | Net Sales to External Customers |                 |                          |                  | Operating Earnings         |               |                          |               |
|---|---------------------------------|-----------------|--------------------------|------------------|----------------------------|---------------|--------------------------|---------------|
|   | Three Months Ended June 30      |                 | Six Months Ended June 30 |                  | Three Months Ended June 30 |               | Six Months Ended June 30 |               |
|   | 2013                            | 2012            | 2013                     | 2012             | 2013                       | 2012          | 2013                     | 2012          |
| Established Pharmaceutical Products                           | \$ 1,218                        | \$ 1,246        | \$ 2,450                 | \$ 2,503         | \$ 258                     | \$ 269        | \$ 543                   | \$ 562        |
| Nutritional Products  | 1,704                           | 1,580           | 3,404                    | 3,142            | 313                        | 214           | 655                      | 474           |
| Diagnostic Products   | 1,135                           | 1,078           | 2,223                    | 2,120            | 242                        | 233           | 503                      | 427           |
| Vascular Products   | 751                             | 766             | 1,492                    | 1,569            | 221                        | 249           | 408                      | 516           |
| Total Reportable Segments                                     | 4,808                           | 4,670           | 9,569                    | 9,334            | 1,034                      | 965           | 2,109                    | 1,979         |
| Other   | 638                             | 643             | 1,255                    | 1,263            |                            |               |                          |               |
| Net Sales   | <u>\$ 5,446</u>                 | <u>\$ 5,313</u> | <u>\$ 10,824</u>         | <u>\$ 10,597</u> |                            |               |                          |               |
| Corporate functions and benefit plans costs                   |                                 |                 |                          |                  | (127)                      | (184)         | (247)                    | (343)         |
| Non-reportable segments                                       |                                 |                 |                          |                  | 99                         | 105           | 187                      | 186           |
| Net interest expense  |                                 |                 |                          |                  | (24)                       | (64)          | (49)                     | (130)         |
| Share-based compensation (a)                                  |                                 |                 |                          |                  | (52)                       | (57)          | (177)                    | (185)         |
| Amortization of intangible assets                             |                                 |                 |                          |                  | (197)                      | (195)         | (396)                    | (404)         |
| Other, net (b)  |                                 |                 |                          |                  | (132)                      | (40)          | (272)                    | (110)         |
| Consolidated Earnings from Continuing Operations Before Taxes |                                 |                 |                          |                  | <u>\$ 601</u>              | <u>\$ 530</u> | <u>\$ 1,155</u>          | <u>\$ 993</u> |

- (a) Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
- (b) Other, net includes the Net foreign exchange loss (gain) in the Condensed Consolidated Statement of Earnings, expenses associated with restructuring programs and other costs. For the six months ended June 30, 2012, it also includes income from the resolution of a contractual agreement.

Notes to Condensed Consolidated Financial Statements  
June 30, 2013  
(Unaudited), continued

Note 9 — Incentive Stock Programs

In connection with the separation of AbbVie on January 1, 2013, Abbott modified its outstanding equity awards granted under incentive stock programs for its employees. The awards were generally modified such that immediately following the separation, the awardees held the same number of awards in Abbott stock and an equal number of awards in AbbVie stock. The exercise price on outstanding Abbott options was adjusted and the exercise price on the AbbVie options granted under this modification was established with the intention of generally preserving the value of the awards immediately prior to the separation. This modification did not result in additional compensation expense.

In the first six months of 2013, Abbott granted 4,410,648 stock options, 856,157 replacement stock options, 835,300 restricted stock awards and 6,065,329 restricted stock units under its incentive stock programs. At June 30, 2013, approximately 130 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2013 is as follows:

|   | Outstanding | Exercisable |
|---|-------------|-------------|
| Number of shares                        | 46,570,725  | 39,436,059  |
| Weighted average remaining life (years) | 4.2         | 3.8         |
| Weighted average exercise price         | \$ 26.13    | \$ 24.99    |
| Aggregate intrinsic value (in millions) | \$ 417      | \$ 398      |



The total unrecognized share-based compensation cost at June 30, 2013 amounted to approximately \$230 million which is expected to be recognized over the next three years.

#### Note 10 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, totaling \$389 million and \$1.6 billion at June 30, 2013 and December 31, 2012, respectively, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Contracts totaling \$1.0 billion were transferred to AbbVie as part of the separation on January 1, 2013. Accumulated gains and losses as of June 30, 2013 will be included in Cost of products sold at the time the products are sold, generally through the next twelve months. The amount of hedge ineffectiveness was not significant in 2013 and 2012.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen. At June 30, 2013 and December 31, 2012, Abbott held \$11.5 billion and \$18.2 billion, respectively, of such foreign currency forward exchange contracts, of which \$4.3 billion of these contracts were transferred to AbbVie as part of the separation on January 1, 2013.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately \$540 million and approximately \$615 million as of June 30, 2013 and December 31, 2012, respectively. Accordingly, changes in the fair value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate swap contracts totaling approximately \$1.5 billion at June 30, 2013 and \$9.5 billion at December 31, 2012 to manage its exposure to changes in the fair value of fixed-rate debt. \$8.0 billion of these contracts related to debt issued by AbbVie Inc. in the fourth quarter of 2012 and were transferred to AbbVie as part of the separation on January 1, 2013. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No hedge ineffectiveness was recorded in income in 2013 or 2012 for these hedges.

#### Notes to Condensed Consolidated Financial Statements

June 30, 2013

(Unaudited), continued

The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2013 and December 31, 2012:

| (dollars in millions)  | Fair Value - Assets |                 |  | Fair Value - Liabilities |                 |  |
|--|---------------------|-----------------|--|--------------------------|-----------------|--|
|  | June 30<br>2013     | Dec. 31<br>2012 | Balance Sheet Caption                        | June 30<br>2013          | Dec. 31<br>2012 | Balance Sheet Caption  |
| Interest rate swaps designated as fair value hedges                  | \$ 104              | \$ 185          | Deferred income taxes and other assets       | \$ —                     | \$ 80           | Post-employment obligations, deferred income taxes and other long-term liabilities |
| Foreign currency forward exchange contracts —                        |                     |                 |  |                          |                 |  |
| Hedging instruments  | 30                  | 22              | Prepaid expenses,                            | —                        | 11              | Other accrued liabilities  |
| Others not designated as hedges                                      | 95                  | 98              | deferred income taxes, and other receivables | 169                      | 135             |  |
| Debt designated as a hedge of net investment in a foreign subsidiary | —                   | —               | n/a  | 540                      | 615             | Short-term borrowings  |
|  | <u>\$ 229</u>       | <u>\$ 305</u>   |  | <u>\$ 709</u>            | <u>\$ 841</u>   |  |

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and the amounts and location of income (expense) and gain (loss) reclassified into income in the second quarter and first six months of 2013 and 2012 and for certain other derivative financial instruments. The amount of hedge ineffectiveness was not significant in 2013 and 2012 for these hedges.

| (dollars in millions)  | Gain (loss) Recognized in Other Comprehensive Income (loss) |       |                          |        | Income (expense) and Gain (loss) Reclassified into Income |       |                          |       | Income Statement Caption |
|--|---|-------|--------------------------|--------|---|-------|--------------------------|-------|--------------------------|
|  | Three Months Ended June 30                                  |       | Six Months Ended June 30 |        | Three Months Ended June 30                                |       | Six Months Ended June 30 |       |                          |
|  | 2013  | 2012  | 2013                     | 2012   | 2013  | 2012  | 2013                     | 2012  |                          |
| Foreign currency forward exchange contracts designated as cash flow hedges | \$ 14   | \$ 52 | \$ 31                    | \$ (2) | \$ 11   | \$ 26 | \$ 14                    | \$ 39 | Cost of products sold    |
| Debt designated as a hedge of net investment in a foreign subsidiary       | 25  | (25)  | 75                       | 10     | n/a   | n/a   | n/a                      | n/a   | n/a                      |
| Interest rate swaps designated as fair value                               | n/a   | n/a   | n/a                      | n/a    | (71)  | 93    | (81)                     | 83    | Interest expense         |

|  |     |     |     |     |    |     |     |     |                                  |
|--|-----|-----|-----|-----|----|-----|-----|-----|----------------------------------|
| hedges   |     |     |     |     |    |     |     |     |                                  |
| Foreign currency forward exchange contracts not designated as hedges | n/a | n/a | n/a | n/a | 50 | 112 | 140 | 138 | Net foreign exchange loss (gain) |

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

Notes to Condensed Consolidated Financial Statements  
June 30, 2013  
(Unaudited), continued

The carrying values and fair values of certain financial instruments as of June 30, 2013 and December 31, 2012 are shown in the table below. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

| (dollars in millions)                               | June 30 2013   |            | December 31 2012 |            |
|---|----------------|------------|------------------|------------|
|   | Carrying Value | Fair Value | Carrying Value   | Fair Value |
| <b>Long-term Investment Securities:</b>             |                |            |                  |            |
| Equity securities                                   | \$ 126         | \$ 126     | \$ 213           | \$ 213     |
| Other   | 28             | 26         | 61               | 56         |
| Total Long-term Debt                                | (3,675)        | (4,189)    | (18,394)         | (19,588)   |
| <b>Foreign Currency Forward Exchange Contracts:</b> |                |            |                  |            |
| Receivable position                                 | 125            | 125        | 120              | 120        |
| (Payable) position                                  | (169)          | (169)      | (146)            | (146)      |
| <b>Interest Rate Hedge Contracts</b>                |                |            |                  |            |
| Receivable position                                 | 104            | 104        | 185              | 185        |
| (Payable) position                                  | —              | —          | (80)             | (80)       |

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

| (dollars in millions)                                     | Outstanding Balances | Basis of Fair Value Measurement |                                     |                                 |
|---|----------------------|---------------------------------|-------------------------------------|---------------------------------|
|   |                      | Quoted Prices in Active Markets | Significant Other Observable Inputs | Significant Unobservable Inputs |
| <b>June 30, 2013:</b>                                     |                      |                                 |                                     |                                 |
| Equity securities   | \$ 62                | \$ 62                           | \$ —                                | \$ —                            |
| Interest rate swap derivative financial instruments       | 104                  | —                               | 104                                 | —                               |
| Foreign currency forward exchange contracts               | 125                  | —                               | 125                                 | —                               |
| Total Assets  | \$ 291               | \$ 62                           | \$ 229                              | \$ —                            |
| Fair value of hedged long-term debt                       | \$ 1,641             | \$ —                            | \$ 1,641                            | \$ —                            |
| Foreign currency forward exchange contracts               | 169                  | —                               | 169                                 | —                               |
| Contingent consideration related to business combinations | 195                  | —                               | —                                   | 195                             |
| Total Liabilities   | \$ 2,005             | \$ —                            | \$ 1,810                            | \$ 195                          |
| <b>December 31, 2012:</b>                                 |                      |                                 |                                     |                                 |
| Equity securities   | \$ 76                | \$ 76                           | \$ —                                | \$ —                            |
| Interest rate swap derivative financial instruments       | 185                  | —                               | 185                                 | —                               |
| Foreign currency forward exchange contracts               | 120                  | —                               | 120                                 | —                               |
| Total Assets  | \$ 381               | \$ 76                           | \$ 305                              | \$ —                            |
| Fair value of hedged long-term debt                       | \$ 9,632             | \$ —                            | \$ 9,632                            | \$ —                            |
| Interest rate swap derivative financial instruments       | 80                   | —                               | 80                                  | —                               |
| Foreign currency forward exchange contracts               | 146                  | —                               | 146                                 | —                               |
| Contingent consideration related to business combinations | 323                  | —                               | —                                   | 323                             |
| Total Liabilities   | \$ 10,181            | \$ —                            | \$ 9,858                            | \$ 323                          |

The fair value of the debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money, exchange, payments and other changes in fair value.

## Note 11 — Goodwill and Intangible Assets

Foreign currency translation adjustments and other adjustments decreased goodwill in the first six months of 2013 and 2012 by approximately \$290 million and approximately \$350 million, respectively. In addition, in connection with the separation of AbbVie on January 1, 2013, Abbott transferred approximately \$6.1 billion of goodwill to AbbVie. The amount of goodwill related to reportable segments at June 30, 2013 was \$2.9 billion for the Established Pharmaceutical Products segment, \$210 million for the Nutritional Products segment, \$386 million for the Diagnostic Products segment, and \$2.7 billion for the Vascular Products segment. Other than the effects of the separation of AbbVie, there were no reductions of goodwill relating to the disposal of all or a portion of a business. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was \$11.8 billion as of June 30, 2013 and \$17.6 billion as of December 31, 2012, and accumulated amortization was \$6.4 billion as of June 30, 2013 and \$9.7 billion as of December 31, 2012. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, was approximately \$258 million at June 30, 2013 and \$691 million at December 31, 2012. Gross amortizable intangible assets, accumulated amortization and indefinite-lived intangible assets of \$5.8 billion, \$3.9 billion and \$416 million, respectively, were transferred to AbbVie as part of the separation on January 1, 2013. Abbott's estimated annual amortization expense for intangible assets is approximately \$795 million in 2013, \$655 million in 2014, \$600 million in 2015, \$580 million in 2016 and \$545 million in 2017. Amortizable intangible assets are amortized over 2 to 20 years (average 11 years).

## Note 12 — Restructuring Plans

In the third quarter 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceutical and nutritionals businesses. Abbott recorded employee related severance charges of approximately \$167 million in 2012. Additional charges of approximately \$22 million were also recorded in 2012, primarily for asset impairments. Approximately \$70 million is recorded in Cost of products sold and approximately \$119 million as Selling, general and administrative expense. Through December 31, 2012, no significant cash payments were made relating to these actions. The following summarizes the activity for these restructurings: (*dollars in millions*)

|  | 2013 |      |
|--|------|------|
| Restructuring charges recorded in 2012 | \$   | 167  |
| Payments and other adjustments         |      | (73) |
| Accrued balance at June 30             | \$   | 94   |

In 2011 and prior years, Abbott management approved plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   | 2013 |      | 2012 |     |
|---|------|------|------|-----|
| Accrued balance at December 31, 2012 and 2011 | \$   | 129  | \$   | 177 |
| Transfer of liability to AbbVie               |      | (62) |      | —   |
| Payments and other adjustments                |      | (40) |      | (6) |
| Accrued balance at June 30                    | \$   | 27   | \$   | 171 |

Additional charges of \$16 million and \$10 million were recorded in the first six months of 2013 and 2012, respectively, relating to these restructurings, primarily for accelerated depreciation.

## Notes to Condensed Consolidated Financial Statements

June 30, 2013

(Unaudited), continued

In 2012 and 2010, Abbott management approved restructuring plans primarily related to the acquisition of Solvay Pharmaceuticals. These plans streamline operations, improve efficiencies and reduce costs in certain sites and functions as well as in certain commercial organizations in various countries. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   | 2013 |       | 2012 |      |
|---|------|-------|------|------|
| Accrued balance at December 31, 2012 and 2011 | \$   | 115   | \$   | 108  |
| Transfer of liability to AbbVie               |      | (115) |      | —    |
| Payments and other adjustments                |      | —     |      | (90) |
| Accrued balance at June 30                    | \$   | —     | \$   | 18   |

In 2011 and 2008, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs, and improve efficiencies in Abbott's core diagnostic business. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   | 2013 |     | 2012 |      |
|---|------|-----|------|------|
| Accrued balance at December 31, 2012 and 2011 | \$   | 56  | \$   | 79   |
| Payments and other adjustments                |      | (6) |      | (17) |
| Accrued balance at June 30                    | \$   | 50  | \$   | 62   |

Additional charges of approximately \$4 million and \$8 million were recorded in the first six months of 2013 and 2012, respectively, relating to this restructuring, primarily for product transfer costs.

## Note 13 — Subsequent Events — Business Acquisitions

In July 2013, Abbott announced that it entered into agreements to acquire IDEV Technologies and OptiMedica. The acquisition of IDEV Technologies will expand Abbott's endovascular portfolio and the acquisition of OptiMedica will provide Abbott with an immediate entry point into the laser assisted cataract surgery market. Under the terms of the agreement, Abbott will acquire all of the outstanding equity of IDEV Technologies for \$310 million, net of cash and debt held by IDEV. Under the terms of the agreement, Abbott will acquire OptiMedica for \$250 million in cash, net of cash held by OptiMedica, plus additional payments totaling up to \$150 million upon completion of certain development, regulatory and sales milestones.

**FINANCIAL REVIEW**

**Results of Operations**

The following table details sales by reportable segment for the three months and six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

| (dollars in millions)               | Net Sales to External Customers |                |          |                |                          |                |           |                |
|-------------------------------------|---------------------------------|----------------|----------|----------------|--------------------------|----------------|-----------|----------------|
|                                     | Three Months Ended June 30      |                |          |                | Six Months Ended June 30 |                |           |                |
|                                     | 2013                            | Percent Change | 2012     | Percent Change | 2013                     | Percent Change | 2012      | Percent Change |
| Established Pharmaceutical Products | \$ 1,218                        | (2.3)          | \$ 1,246 | (6.0)          | \$ 2,450                 | (2.1)          | \$ 2,503  | (3.9)          |
| Nutritional Products                | 1,704                           | 7.9            | 1,580    | 6.3            | 3,404                    | 8.3            | 3,142     | 8.2            |
| Diagnostic Products                 | 1,135                           | 5.3            | 1,078    | 3.8            | 2,223                    | 4.9            | 2,120     | 4.9            |
| Vascular Products                   | 751                             | (2.0)          | 766      | (8.3)          | 1,492                    | (4.9)          | 1,569     | (6.6)          |
| Total Reportable Segments           | 4,808                           | 3.0            | 4,670    | (0.3)          | 9,569                    | 2.5            | 9,334     | 1.4            |
| Other                               | 638                             | (0.8)          | 643      | (1.9)          | 1,255                    | (0.7)          | 1,263     | (1.1)          |
| Net Sales                           | \$ 5,446                        | 2.5            | \$ 5,313 | (0.5)          | \$ 10,824                | 2.1            | \$ 10,597 | 1.1            |
| Total U.S.                          | \$ 1,560                        | (2.8)          | \$ 1,605 | 3.0            | \$ 3,094                 | (3.0)          | \$ 3,191  | 3.7            |
| Total International                 | \$ 3,886                        | 4.8            | \$ 3,708 | (2.0)          | \$ 7,730                 | 4.4            | \$ 7,406  | —              |

The net sales growth for the second quarter and first six months of 2013 reflects unit growth, partially offset by unfavorable exchange. Excluding 1.7 percent of unfavorable exchange for the second quarter and first six months of 2013, net sales increased 4.2 percent and 3.8 percent, respectively. The relatively stronger U.S. dollar decreased second quarter 2013 Total International sales by 2.4 percent, decreased Established Pharmaceutical Products segment sales by 2.5 percent, decreased Nutritional Product segment sales by 0.5 percent, decreased Diagnostic Products segment sales by 2.3 percent and decreased Vascular Products segment sales by 1.9 percent over the second quarter of 2012. The relatively stronger U.S. dollar decreased the first six months 2013 Total International sales by 2.4 percent, decreased Established Pharmaceutical Products segment sales by 2.8 percent, decreased Nutritional Product segment sales by 0.4 percent, decreased Diagnostic Products segment sales by 2.1 percent and decreased Vascular Products segment sales by 1.8 percent over the first six months of 2012. In addition to unfavorable exchange, the decrease in 2013 and 2012 Vascular Products sales reflects the winding down of royalty and supply agreements related to certain third-party products, including Promus. Excluding this royalty and supply agreement revenue in both periods and the unfavorable effect of exchange, year-to-date Vascular Products sales decreased 0.9 percent in 2013 and increased 4.5 percent in 2012. The decrease in 2013 is due primarily to pricing pressures on drug eluting stents and other coronary products as a result of market competition in major markets, partially offset by the sales of new products.

The net sales growth for the second quarter and first six months of 2012 reflects unit growth, partially offset by unfavorable exchange. Excluding 5.0 percent and 3.2 percent of unfavorable exchange for the second quarter and first six months of 2012, net sales increased 4.5 percent and 4.3 percent, respectively. The relatively stronger U.S. dollar decreased second quarter 2012 Total International sales by 7.0 percent, decreased Established Pharmaceutical Products segment sales by 9.8 percent, decreased Nutritional Product segment sales by 2.0 percent, decreased Diagnostic Products segment sales by 4.9 percent and decreased Vascular Products segment sales by 3.6 percent over the second quarter of 2011. The relatively stronger U.S. dollar decreased the first six months 2012 Total International sales by 4.6 percent, decreased Established Pharmaceutical Products segment sales by 6.7 percent, decreased Nutritional Product segment sales by 1.2 percent, decreased Diagnostic Products segment sales by 3.2 percent and decreased Vascular Products segment sales by 2.0 percent over the first six months of 2011.

**FINANCIAL REVIEW**

(continued)

A comparison of significant product group sales for the six months ended June 30 is as follows. Percent changes are versus the prior year and are based on unrounded numbers.

| (dollars in millions)                       | 2013     | Percent Change | 2012     | Percent Change |
|---|----------|----------------|----------|----------------|
| Established Pharmaceutical Products sales — |          |                |          |                |
| Key Emerging Markets                        | \$ 1,175 | 3              | \$ 1,136 | 3              |
| Other Markets                               | 1,275    | (7)            | 1,367    | (9)            |
| Nutritionals —                              |          |                |          |                |
| U.S. Pediatric Nutritionals                 | 756      | —              | 759      | 20             |
| International Pediatric Nutritionals        | 1,193    | 21             | 990      | 7              |
| U.S. Adult Nutritionals                     | 677      | (1)            | 681      | 5              |
| International Adult Nutritionals            | 778      | 9              | 712      | 2              |

|  |       |     |       |     |
|--|-------|-----|-------|-----|
| Diagnostics —  |       |     |       |     |
| Immunochemistry  | 1,696 | 4   | 1,630 | 5   |
| Vascular Products (1) —  |       |     |       |     |
| Drug Eluting Stents (DES) and Bioresorbable Vascular Scaffold (BVS) products | 776   | (3) | 804   | 4   |
| Other Coronary products  | 292   | (3) | 302   | (2) |
| Endovascular   | 234   | 2   | 228   | 1   |

(1) Other Coronary Products include primarily guidewires and balloon catheters. Endovascular includes vessel closure, carotid stents and other peripheral products.

The Established Pharmaceutical Products segment is focused on 14 key emerging markets including India, Russia, China and Brazil. Sales in Other Markets in the Established Pharmaceutical Products segment decreased in 2013 and 2012 due primarily to price declines from the continued effect of European austerity measures, the impact of 2012 price reductions in Japan, and unfavorable exchange. U.S. Pediatric sales were flat in 2013 due to lower formula share in the Supplemental Nutrition Program for Women, Infants and Children (WIC) segment, partially offset by higher revenue from toddler products. In 2012, U.S. Pediatric Nutritional sales reflect market share gains for *Similac*, including the recovery from the September 2010 voluntary recall as well as unit growth for Pediatric Nutritionals. International Pediatric Nutritionals sales increased in 2013 and 2012 due primarily to volume growth in developing countries. U.S. Adult Nutritional sales in 2013 were negatively impacted by the exit from certain non-core business lines as part of the business' margin improvement initiative. In the Vascular Products segment, decreased sales of DES and Other Coronary products in 2013 primarily reflect pricing pressure as a result of market competition in major markets.

The gross profit margin was 49.7 percent for the second quarter 2013 compared to 51.7 percent for the second quarter 2012. First six months 2013 gross profit margin was 50.4 percent compared to 51.6 percent in the first six months 2012. The second quarter and first six months 2013 gross margins reflect pricing pressure in certain developed markets, product mix, the negative effect of exchange in the second quarter and costs associated with various restructuring programs. This was partially offset by improved gross margins in the nutritional segment in the second quarter and in the nutritional and diagnostics segments for the six months ended June 30, 2013.

Research and development expenses decreased 2.2 percent and 3.5 percent in the second quarter and first six months 2013, respectively, due primarily to the timing of expenditures. For the first six months ended June 30, 2013, research and development expenditures totaled \$167 million for the Vascular Products segment, \$200 million for the Diagnostics Products segment, \$116 million for the Established Pharmaceutical Products segment and \$89 million for the Nutritional Products segment.

Selling, general and administrative expenses for the second quarter and first six months 2013 decreased 5.5 percent and 4.3 percent, respectively, due primarily to the inclusion in 2012 of certain corporate costs that transferred to AbbVie in the separation, as well as certain costs that are being charged to AbbVie under transitional services agreements in 2013.

## FINANCIAL REVIEW (continued)

### Restructuring Plans

In the third quarter 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceutical and nutritionals businesses. Abbott recorded employee related severance charges of approximately \$167 million in 2012. Additional charges of approximately \$22 million were also recorded in 2012, primarily for asset impairments. Approximately \$70 million is recorded in Cost of products sold and approximately \$119 million as Selling, general and administrative expense. Through December 31, 2012, no significant cash payments were made relating to these actions. The following summarizes the activity for these restructurings: (*dollars in millions*)

|  | 2013 |      |
|--|------|------|
| Restructuring charges recorded in 2012 | \$   | 167  |
| Payments and other adjustments         |      | (73) |
| Accrued balance at June 30             | \$   | 94   |

In 2011 and prior years, Abbott management approved plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   | 2013 |      | 2012 |     |
|---|------|------|------|-----|
| Accrued balance at December 31, 2012 and 2011 | \$   | 129  | \$   | 177 |
| Transfer of liability to AbbVie               |      | (62) |      | —   |
| Payments and other adjustments                |      | (40) |      | (6) |
| Accrued balance at June 30                    | \$   | 27   | \$   | 171 |

Additional charges of \$16 million and \$10 million were recorded in the first six months of 2013 and 2012, respectively, relating to these restructurings, primarily for accelerated depreciation.

In 2012 and 2010, Abbott management approved restructuring plans primarily related to the acquisition of Solvay Pharmaceuticals. These plans streamline operations, improve efficiencies and reduce costs in certain sites and functions as well as in certain commercial organizations in various countries. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   |    |       |    |      |
|---|----|-------|----|------|
| Accrued balance at December 31, 2012 and 2011 | \$ | 115   | \$ | 108  |
| Transfer of liability to AbbVie               |    | (115) |    | —    |
| Payments and other adjustments                |    | —     |    | (90) |
| Accrued balance at June 30                    | \$ | —     | \$ | 18   |

In 2011 and 2008, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs, and improve efficiencies in Abbott's core diagnostic business. The following summarizes the activity for these restructurings: (*dollars in millions*)

|   | 2013  | 2012  |
|---|-------|-------|
| Accrued balance at December 31, 2012 and 2011 | \$ 56 | \$ 79 |
| Payments and other adjustments                | (6)   | (17)  |
| Accrued balance at June 30                    | \$ 50 | \$ 62 |

Additional charges of approximately \$4 million and \$8 million were recorded in the first six months of 2013 and 2012, respectively, relating to this restructuring, primarily for product transfer costs.

#### Interest Expense (Income)

Interest expense decreased in the second quarter and first six months of 2013 compared to 2012 due to a lower level of borrowings.

## FINANCIAL REVIEW

(continued)

#### Other (Income) Expense, net

Other (income) expense, net, for the first six months 2012 includes income of approximately \$40 million from the resolution of a contractual agreement.

#### Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. The effective tax rates are less than the statutory U.S. federal income tax rate principally due to the benefit of lower statutory tax rates and tax exemptions in several foreign taxing jurisdictions. As a result of the American Taxpayer Relief Act of 2012 signed into law in January 2013, Abbott recorded a tax benefit to taxes on continuing operations of approximately \$103 million in the first quarter of 2013 for the retroactive extension of the research tax credit and the look-through rules of section 954(c)(6) of the Internal Revenue Code to the beginning of 2012. Tax authorities in various jurisdictions regularly review Abbott's income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by \$550 million to \$650 million, including cash adjustments, within the next twelve months as a result of concluding various tax matters.

#### Separation of AbbVie Inc.

On November 28, 2012, Abbott's board of directors declared a special dividend distribution of all of the outstanding shares of common stock of AbbVie Inc. (AbbVie), the company formed to hold Abbott's research-based proprietary pharmaceuticals business. For each Abbott common share held at the close of business on December 12, 2012, Abbott shareholders received one share of AbbVie stock on January 1, 2013. Abbott has received a ruling from the Internal Revenue Service that the separation qualifies as a tax-free distribution to Abbott and its U.S. shareholders for U.S. federal income tax purposes.

The historical results of operations of the research-based proprietary pharmaceuticals business have been presented as discontinued operations in the Condensed Consolidated Statement of Earnings. Discontinued operations include the results of AbbVie's business except for certain corporate overhead costs and certain costs associated with transition services that will be provided by Abbott to AbbVie. Discontinued operations also includes other costs incurred by Abbott to separate AbbVie as well as an allocation of interest assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. Prior-year balance sheets and statements of cash flows have not been adjusted to reflect the effect of the separation.

The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013: (*dollars in billions*)

|  |               |
|--|---------------|
| <b>Assets:</b>   |               |
| Cash and cash equivalents  | \$ 5.9        |
| Investments  | 2.2           |
| Trade receivables, less allowances   | 3.2           |
| Inventories  | 0.7           |
| Prepaid expenses, deferred income taxes, and other current receivables             | 2.9           |
| Net property and equipment   | 2.2           |
| Intangible assets, net of amortization   | 2.3           |
| Goodwill   | 6.1           |
| Deferred income taxes and other assets   | 1.6           |
|  | <u>27.1</u>   |
| <b>Liabilities:</b>  |               |
| Short-term borrowings  | 1.0           |
| Trade accounts payable and other current liabilities                               | 5.1           |
| Long-term debt   | 14.6          |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1           |
|  | <u>23.8</u>   |
| Net Assets Transferred to AbbVie Inc.  | \$ <u>3.3</u> |

FINANCIAL REVIEW  
(continued)

In addition, approximately \$1.1 billion of accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation was transferred to AbbVie.

Summarized financial information for discontinued operations for 2012 is as follows: *(dollars in millions)*

|                       | Three Months Ended<br>June 30, 2012 | Six Months Ended<br>June 30, 2012 |
|-----------------------|-------------------------------------|-----------------------------------|
| Net sales             | \$ 4,494                            | \$ 8,667                          |
| Earnings before taxes | 1,473                               | 2,523                             |
| Taxes on earnings     | 159                                 | 318                               |
| Net earnings          | 1,314                               | 2,205                             |

Abbott and AbbVie entered into transitional services agreements prior to the separation pursuant to which Abbott and AbbVie are providing to each other, on an interim transitional basis, various services. Transition services may be provided for up to 24 months with an option for a one-year extension by the recipient. Services being provided by Abbott include certain information technology and back office support. Billings by Abbott under these transitional services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transitional support will enable AbbVie to establish its stand-alone processes for various activities that were previously provided by Abbott and does not constitute significant continuing support of AbbVie's operations.

For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations are expected to be transferred to AbbVie in 2013 with the remainder transferring in 2014. These assets and liabilities have been presented as held for disposition in the Condensed Consolidated Balance Sheet. At June 30, 2013, the assets and liabilities held for disposition consist of inventories of \$180 million, trade accounts receivable of \$319 million, equipment of \$30 million, other assets of \$75 million, trade accounts payable of \$243 million and other liabilities of \$65 million. Abbott's obligation to transfer the net assets held for disposition to AbbVie of \$296 million is included in Other accrued liabilities.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. In connection with the separation, Abbott has adjusted its employee stock compensation awards and separated its defined benefit programs for pensions and post-employment medical and dental benefit plans.

Liquidity and Capital Resources June 30, 2013 Compared with December 31, 2012

The reduction of cash and cash equivalents from \$10.8 billion at December 31, 2012 to \$5.6 billion at June 30, 2013 reflects the transfer of \$5.9 billion of cash and cash equivalents to AbbVie as part of the separation on January 1, 2013.

Net cash from operating activities for the first six months 2013 totaled approximately \$1.2 billion. The (\$555) million in the Other, net category in net cash from operating activities reflects approximately \$435 million of one-time net cash outflows related to the separation of AbbVie, the first quarter noncash impact of the \$103 million tax benefit for the retroactive impact of U.S. tax law changes due to the timing of tax filings and the effects of \$320 million of contributions to defined benefit plans. Other, net in Net cash from operating activities for 2012 includes payments of approximately \$800 million to settle certain government investigations related to AbbVie's business operations. In addition, Other, net in Net cash from operating activities for 2012 includes the effects of contributions to defined benefit plans of \$320 million. Abbott expects annual cash flow from operating activities to continue to exceed Abbott's capital expenditures and cash dividends.

Working capital was \$8.9 billion at June 30, 2013 and \$18.0 billion at December 31, 2012. The decrease in working capital in 2013 is due primarily to the separation of AbbVie from Abbott on January 1, 2013.

FINANCIAL REVIEW  
(continued)

Substantially all of Abbott's trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. Outstanding net governmental receivables in these countries at June 30, 2013 were: *(dollars in millions)*

|          | Net<br>Receivables | Percentage Over<br>One Year Past Due |
|----------|--------------------|--------------------------------------|
| Italy    | \$ 246             | 16.6                                 |
| Spain    | 146                | 10.1                                 |
| Portugal | 44                 | 37.0                                 |
| Greece   | 30                 | 32.4                                 |

Abbott closely monitors economic conditions and budgetary and other fiscal developments in these countries. Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate risk although such arrangements were not material in the first six months of 2013.

At June 30, 2013 Abbott's long-term debt rating was A+ by Standard & Poor's Corporation and A1 by Moody's Investors Service. Abbott has readily available financial resources, including unused lines of credit of \$5.0 billion that support commercial paper borrowing arrangements which expire in 2017.

In October 2008, the board of directors authorized the purchase of up to \$5 billion of Abbott's common shares from time to time and 32.9 million and 27.2 million shares were purchased in the first six months of 2013 and 2012, respectively, under this authorization at a cost of approximately \$1.2 billion and \$1.6 billion, respectively. Effective in the second quarter 2013, no additional purchases of common shares will be made from this authorization. In June 2013, the board of directors authorized the purchase of up to \$3.0 billion of Abbott's common shares from time to time.

In the first two quarters of 2013, Abbott declared a dividend of \$0.14 per share each quarter on its common shares. The change in the dividend compared to 2012 reflects the impact of the separation of AbbVie.

### Legislative Issues

In 2010, the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively referred to herein as "health care reform legislation") were signed into law in the U.S. Beginning in 2013, Abbott started recording a 2.3 percent excise tax imposed by health care reform legislation on the sale of certain medical devices in the U.S.

Abbott's primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2012 Annual Report on Form 10-K/A.

### Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, in the 2012 Annual Report on Form 10-K/A.

---

## PART I. FINANCIAL INFORMATION

### Item 4. Controls and Procedures

- (a) *Evaluation of disclosure controls and procedures.* The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Thomas C. Freyman, evaluated the effectiveness of Abbott Laboratories' disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories' disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
- (b) *Changes in internal control over financial reporting.* During the quarter ended June 30, 2013, there were no changes in Abbott's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott's internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including (as of June 30, 2013, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

In its 2012 Annual Report on Form 10-K/A, Abbott reported that Cordis Corporation and Wyeth sued Abbott in the United States District Court for the District of New Jersey alleging that the Xience V stent infringes certain of their patents, and that in June 2012, Cordis and Wyeth appealed the district court's order invalidating the patents. On June 26, 2013, the appeals court affirmed the district court's order invalidating the patents.

In its 2012 Annual Report on Form 10-K/A, Abbott reported that in connection with the separation of AbbVie Inc., AbbVie is responsible for certain investigations, claims and litigation matters relating to Abbott's former research-based pharmaceuticals business. AbbVie has been substituted for Abbott in its previously reported case filed against Roxane Laboratories in the United States District Court for the District of Delaware seeking to enforce its patent rights relating to ritonavir tablets (a drug Abbott sells under the trademark Norvir®). Abbott is no longer a party to the Delaware proceeding.

---

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

#### (c) *Issuer Purchases of Equity Securities*



|                                | Number of Shares (or Units) Purchased | Price Paid per Share (or Unit) | of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|--------------------------------|---------------------------------------|--------------------------------|--|---|
| April 1, 2013 — April 30, 2013 | 189,067(1)                            | \$ 36.364                      | 0  | \$ 302,271,964(2)   |
| May 1, 2013 — May 31, 2013     | 7,099,169(1)                          | \$ 37.780                      | 7,000,000  | \$ 37,732,964(2)  |
| June 1, 2013 — June 30, 2013   | 981,021(1)                            | \$ 36.845                      | 962,000  | \$ 3,000,000,000(2)   |
| Total                          | 8,269,257(1)                          | \$ 37.637                      | 7,962,000  | \$ 3,000,000,000(2)   |

(1) These shares include:

- (i) the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options — 189,067 in April, 64,169 in May, and 19,021 in June; and
- (ii) the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan - 0 in April, 35,000 in May, and 0 in June.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

- (2) On October 13, 2008, Abbott announced that its board of directors approved the purchase of up to \$5 billion of its common shares, from time to time (the “2008 Plan”). The purchases indicated in this table were made pursuant to the 2008 Plan. On June 14, 2013, Abbott announced that its board of directors approved the purchase of up to \$3 billion of its common shares, from time to time. Abbott will not make any further purchases against the unused portion under the 2008 Plan.

23

## Item 6. Exhibits

Incorporated by reference to the Exhibit Index included herewith.

24

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES

By: /s/ Thomas C. Freyman  
 Thomas C. Freyman  
 Executive Vice President,  
 Finance and Chief Financial Officer

Date: August 6, 2013

25

## EXHIBIT INDEX

| Exhibit No.   | Exhibit  |
|---|--|
| 12  | Statement re: computation of ratio of earnings to fixed charges.   |
| 31.1  | Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).  |
| 31.2  | Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).  |
| Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934. |  |
| 32.1  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, filed on August 6, 2013, formatted in XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Cash Flows; (iii) Condensed Consolidated Balance Sheet; and (iv) the notes to the condensed consolidated financial statements.

## Abbott Laboratories

## Computation of Ratio of Earnings to Fixed Charges

(Unaudited)

*(dollars in millions)*

|  | Six Months Ended<br>June 30, 2013 |
|--|-----------------------------------|
| Net Earnings   | \$ 1,021                          |
| Add (deduct):  |                                   |
| Taxes on earnings  | 134                               |
| Capitalized interest cost, net of amortization                 | (2)                               |
| Noncontrolling interests                                       | 6                                 |
| Earnings from Operations, as adjusted                          | <u>1,159</u>                      |
| Fixed Charges:   |                                   |
| Interest on long-term and short-term debt                      | 81                                |
| Capitalized interest cost                                      | 6                                 |
| Rental expense representative of an interest factor            | 29                                |
| Total Fixed Charges  | <u>116</u>                        |
| Total adjusted earnings available for payment of fixed charges | <u>\$ 1,275</u>                   |
| Ratio of earnings to fixed charges                             | <u>11.0</u>                       |

NOTE: For the purpose of calculating this ratio, (i) earnings have been calculated by adjusting earnings for taxes on earnings; interest expense; capitalized interest cost, net of amortization; noncontrolling interests; and the portion of rentals representative of the interest factor, (ii) Abbott considers one-third of rental expense to be the amount representing return on capital, and (iii) fixed charges comprise total interest expense, including capitalized interest and such portion of rentals.

**Certification of Chief Executive Officer  
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))**

I, Miles D. White, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
  4. Abbott's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
    - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    - c) Evaluated the effectiveness of Abbott's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    - d) Disclosed in this report any change in Abbott's internal control over financial reporting that occurred during Abbott's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott's internal control over financial reporting; and
- 
5. Abbott's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott's auditors and the audit committee of Abbott's board of directors:
    - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott's ability to record, process, summarize and report financial information; and
    - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott's internal control over financial reporting.

Date: August 6, 2013

/s/ Miles D. White

Miles D. White, Chairman of the Board  
and Chief Executive Officer

---

**Certification of Chief Financial Officer  
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))**

I, Thomas C. Freyman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
  4. Abbott's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
    - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    - c) Evaluated the effectiveness of Abbott's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    - d) Disclosed in this report any change in Abbott's internal control over financial reporting that occurred during Abbott's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott's internal control over financial reporting; and
- 
5. Abbott's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott's auditors and the audit committee of Abbott's board of directors:
    - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott's ability to record, process, summarize and report financial information; and
    - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott's internal control over financial reporting.

Date: August 6, 2013

/s/ Thomas C. Freyman

Thomas C. Freyman, Executive Vice President,  
Finance and Chief Financial Officer

---

**Certification Pursuant To  
18 U.S.C. Section 1350  
As Adopted Pursuant To  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Abbott Laboratories (the "Company") on Form 10-Q for the period ended June 30, 2013 as filed with the Securities and Exchange Commission (the "Report"), I, Miles D. White, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Miles D. White

---

Miles D. White  
Chairman of the Board and  
Chief Executive Officer  
August 6, 2013

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

---

**Certification Pursuant To  
18 U.S.C. Section 1350  
As Adopted Pursuant To  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Abbott Laboratories (the "Company") on Form 10-Q for the period ended June 30, 2013 as filed with the Securities and Exchange Commission (the "Report"), I, Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Thomas C. Freyman

---

Thomas C. Freyman  
Executive Vice President, Finance  
and Chief Financial Officer  
August 6, 2013

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

---